1 / 19

Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with

Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial. Frederick Feit, Steven Manoukian, Ramin Ebrahimi, Charles Pollack, Magnus Ohman, Michael Attubato, Roxana Mehran and Gregg Stone.

Download Presentation

Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven Manoukian, Ramin Ebrahimi, Charles Pollack, Magnus Ohman, Michael Attubato, Roxana Mehran and Gregg Stone

  2. Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Conflicts: Shareholder: Johnson and Johnson, Medicines Co., Millenium Pharmaceuticals; Consultant: Medicines Co.

  3. ACS in Diabetics: Metabolic Abnormalities • Increased blood glucose causes coronary artery inflammation and is prothrombotic • Increased generation of thrombin, CRP, fibrinogen, von Willebrand factor, factors VII and VIII, and platelet factor 4 • Increased expression of platelet activation markers including p-selectin, which mediates platelet-leukocyte interactions • Higher proportion of platelets expressing GPIIb/IIIa receptors

  4. ACS in Diabetics: Background • Based on prior data including a meta-analysis of ACS trials current clinical guidelines recommend the use of GPIIb/IIIa inhibitors (GPI) in diabetic patients with ACS, especially those in whom PCI is planned1 • In the ACUITY Trial 13,819 pts, including 3852 diabetics, with moderate or high risk ACS, undergoing an early invasive strategy were randomly assigned to either the standard of care: Heparin (UFH or enoxaparin) + GPI; or, Bivalirudin + GPI; or Bivalirudin with provisional GPI 1. Roffi et al. Circulation.2001;104:2767-71

  5. ACS in Diabetics: Methods • We compared adverse events: composite ischemia (death, nonfatal MI, unplanned ischemia driven revascularization), major bleeding and net clinical outcome (composite ischemia or bleeding) within the first 30 days in diabetic vs. nondiabetic pts • We compared the same 30-day end points in diabetic pts by treatment group

  6. ACUITY Design ACS: Unstable angina or NSTEMI, N=13,819 Chest pain >10’ within 24 hours, plus Biomarker +, or Dynamic ECG changes, or Documented CAD or all other TIMI risk criteria ASA Clopidogrel per local practice Prior UFH, LMWH (1 dose), eptifibatide and tirofiban allowed Bivalirudin + IIb/IIIa inhibitor Bivalirudin + provisional IIb/IIIa Enoxaparin or UFH + IIb/IIIa inhibitor Cath within 72 hours PCI, CABG or medical management 30 day endpoints Death, MI, IUR, ACUITY major bleeding (net clinical outcome) Stone et al. Presented 2006; ACC

  7. Study Medications • Anti-thrombin agents (started pre angiography) 1 Target aPTT 50-75 seconds 2 If last enoxaparin dose ≥8h - <16h before PCI; 3 If maintenance dose discontinued or ≥16h from last dose 4 Discontinued at end of PCI with option to continue at 0.25mg/kg for 4-12h if IIb/IIIa inhibitor not used 5 Bivalirudin option for off-pump same as PCI dose. For on-pump bivalirudin discontinued 2 hours before 6 Option to continue with pre-PCI anti-thrombotic regimen at physician discretion

  8. ACS in Diabetics: Angiographic Triage * - p<0.001

  9. ACS in Diabetics: Baseline Characteristics * CrCL <60 mL/min

  10. ACS in Diabetics: 30-Day Outcomes Diabetes vs. No Diabetes P = 0.0002 P = 0.0037 P = 0.0002 †Heparin=unfractionated or enoxaparin

  11. Diabetic ACS Patients Baseline Characteristics by Treatment * creatinine clearance <60 mL/min †Heparin = unfractionated or enoxaparin

  12. P = 0.94 P = 0.64 P = 0.43 Diabetic ACS Patients: 30-Day Endpoints by Treatment Group Heparin* + GP IIb/IIIa vs. Bivalirudin + GP IIb/IIIa *Heparin = unfractionated or enoxaparin

  13. P = 0.02 P = 0.39 P=0.0002 Diabetic ACS Patients: 30-Day Endpoints Heparin* + GP IIb/IIIa vs. Bivalirudin alone *Heparin = unfractionated or enoxaparin

  14. P = 0.39 P = 0.32 P= 0.27 P = 0.37 Diabetic ACS Patients: Components of Ischemic Endpoint Heparin* + IIb/IIIa vs. Bivalirudin Alone *Heparin=unfractionated or enoxaparin

  15. Diabetic ACS Patients: Myocardial Infarction Classification* Heparin† + IIb/IIIa vs. Bivalirudin Alone p = 0.27 5.6% 4.7% 30 day events (%) Q-wave 1.6% p = 0.05 Q-wave 0.8% Non Q-wave Non Q-wave p = 0.87 3.9% 4.0% Heparin + IIb/IIIa Bivalirudin alone (N=1298) (N=1287) *CEC-adjudicated †Heparin=unfractionated or enoxaparin

  16. Diabetic ACS Patients: Bleeding Endpoints 30-days *P value for bivalirudin alone vs. heparin + IIb/IIIa inhibitor †Heparin=unfractionated or enoxaparin

  17. Insulin-dependent Diabetic ACS Patients: 30-Day Endpoints by Treatment Group Heparin† + GP IIb/IIIa vs. Bivalirudin alone P = 0.23 P = 0.74 P = 0.04 †Heparin=unfractionated or enoxaparin

  18. Diabetic Patients with ACS : Conclusions • Compared with non-diabetics, diabetic patients have worse net clinical outcomes at 30 days (12.8% vs. 10.5%; p=0.0002), resulting from significantly higher rates of the composite ischemic end point (8.6% vs. 7.2%; p=0.0037) and non-CABG major bleeding (5.7% vs. 4.2%; p=0.0002) • In diabetic patients, compared with the standard of care, heparin (UFH or enoxaparin) + GPIIb/IIIa, bivalirudin + GPIIb/IIIa was not better for protection from ischemic events or bleeding and resulted in similar net clinical outcome

  19. Diabetic Patients with ACS: Conclusions • Compared to those receiving the reference standard, diabetics receiving bivalirudin monotherapy, with provisional GPIIb/IIIa in 7.9%, had similar protection from ischemic events (7.8% vs. 8.8%; p=0.39) and a marked reduction in major bleeding (3.7% vs. 7.1%; p=0.0002) with improved net clinical outcome (10.8% vs. 13.7%; p=0.02) • These 30-day outcomes suggest that bivalirudin monotherapy is safe and effective for diabetic patients with ACS, including those requiring insulin • One-year clinical and economic data will determine whether this regimen will become the standard of care for these patients.

More Related